SPOTLIGHT -
Retina Specialist
Granite Bay, California
Current Treatment Options for nAMD
Read More
Significance of SRF vs IRF in nAMD
Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).
Markers of Disease Progression in nAMD Patients
Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).
Treat and Extend Strategy for Anti-VEGF Injections
Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.
Real-World Long-Term Safety Data of Anti-VEGF Agents
Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.
Patient and Cross-Care Education Strategies for AMD and DME
Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
Barriers to Optimal Treatment Outcomes
Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
Overview of Anti-VEGF Treatments for AMD and DME
Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
